Foster & Motley Inc. Invests $244,000 in Henry Schein, Inc. $HSIC

Foster & Motley Inc. bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSICFree Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,336 shares of the company’s stock, valued at approximately $244,000.

A number of other large investors have also modified their holdings of HSIC. GAMMA Investing LLC grew its holdings in shares of Henry Schein by 37.8% in the first quarter. GAMMA Investing LLC now owns 3,939 shares of the company’s stock valued at $270,000 after purchasing an additional 1,081 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Henry Schein by 0.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 53,134 shares of the company’s stock worth $3,639,000 after buying an additional 243 shares during the period. State of Alaska Department of Revenue boosted its stake in Henry Schein by 2.8% during the first quarter. State of Alaska Department of Revenue now owns 14,611 shares of the company’s stock worth $1,000,000 after buying an additional 395 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in Henry Schein by 5.2% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,745 shares of the company’s stock worth $941,000 after buying an additional 678 shares during the period. Finally, Figure 8 Investment Strategies LLC lifted its position in shares of Henry Schein by 11.5% during the first quarter. Figure 8 Investment Strategies LLC now owns 8,667 shares of the company’s stock worth $594,000 after purchasing an additional 895 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Up 1.5%

Shares of NASDAQ:HSIC opened at $62.98 on Monday. The firm’s 50 day moving average price is $67.12 and its 200 day moving average price is $68.60. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSICGet Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm’s revenue was up 3.3% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, equities research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HSIC has been the topic of several research reports. Stifel Nicolaus reissued a “hold” rating and set a $75.00 price target (down previously from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Leerink Partners set a $75.00 price target on shares of Henry Schein in a research report on Monday, July 14th. Robert W. Baird reissued a “neutral” rating and set a $72.00 price target (down previously from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Evercore ISI raised shares of Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price target on the stock in a research report on Tuesday, August 26th. Finally, Baird R W cut shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Five equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $76.67.

Read Our Latest Stock Analysis on Henry Schein

About Henry Schein

(Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Stories

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.